Skip to main content

ELB011 (Anti-CD160 antibody in ophthalmology)

ELB011 (Anti-CD160 antibody in ophthalmology)

Antibody to treat Age-related Macular Degeneration
Status: Candidate for the clinic selected

ELSALYS BIOTECH has developed a program based on the anti-angiogenic properties of the anti-CD160 antibody to treat vascular eye diseases and in particular Age-related Macular Degeneration (AMD).

Since this therapeutic domain is outside of the strategic field of activity of the company, ELSALYS BIOTECH has established a partnership with the THÉA Laboratories, a French pharmaceutical company specialized in ophthalmology, to develop this product under licence.

logo THEA

Mechanism of action of ELB011

ELSALYS BIOTECH has already performed preclinical studies with very promising results:

  • In rabbits, treatment with anti-CD160 blocks the formation of new blood vessels, similar to anti-VEGF agents, in a model of induced corneal angiogenesis
  • A combination treatment between an anti-CD160 and an anti-VEGF potentiates the anti-angiogenic effect, suggesting that the two biological pathways are at least partially independent
  • A first generation anti-CD160 limits the number of severe lesions induced with a laser and promotes their healing

Development plan and partnership with the THÉA Laboratories

On the basis of these results, ELSALYS BIOTECH has signed in January 2018 a licence option with the THÉA group for programme ELB011.

The next steps planned in the framework of this agreement are:

  • By the end of 2018: ELSALYS BIOTECH will continue the preclinical assays aiming for a proof of concept for the use of anti-CD160 antibodies in ophthalmology. The THÉA Laboratories will be able to exercise the option.
  • By the end of 2019: ELSALYS BIOTECH will perform, in name of THÉA Laboratories, the regulatory pre-clinical studies and will prepare the application to request an authorisation to perform a first clinical trial
  • By the end of 2020: the THÉA Laboratories will initiate the clinical development (as mono- and combination therapy).

Through this agreement, ELSALYS BIOTECH adds value to this first asset, demonstrates its ability to conclude partnerships with industry counterparts and, if successful, this partnership should become a complementary financial resource for the development of the Company.

Latest news on ELB011

Discover our latest news regarding our pipeline, our partnerships and more

Mon, 07/02/2018 - 15:00 - Fri, 07/02/2021 - 15:30
  • Efficacy and safety are consistently demonstrated in several in vivo preclinical models
  • Anti-CD160 is a potent inhibitor of ocular v
Thu, 02/22/2018 - 17:00
  • ELB011, a first-in-class antibody program, demonstrates an anti-angiogenic effect on the formation of new blood vessels which cause cert

Tue, 02/16/2016 - 17:00
  • Having acquired in June 2015 the assets of CD160 in the field of ophthalmology, ElsaLys Biotech strengthens its intellectual property an


Subcribe to our newsletter